These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 322860)
1. A cytokinetic analysis of bacillus calmette-guérin-induced growth control of a murine leukemia. Olsson L; Mathé G Cancer Res; 1977 Jun; 37(6):1743-9. PubMed ID: 322860 [TBL] [Abstract][Full Text] [Related]
2. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity. Shapiro A; Ratliff TL; Oakley DM; Catalona WJ Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of Bacillus Calmette-Guérin-induced suppression of metastases in a poorly immunogenic fibrosarcoma. Liotta LA; Kleinerman J; Saidel GM Cancer Res; 1976 Sep; 36(9 pt.1):3255-9. PubMed ID: 788897 [TBL] [Abstract][Full Text] [Related]
4. Tumor cytokinetics in the presence of normal, alloimmune, or Bacillus Calmette-Guérin-activated host cells simultaneously assayed in vivo and in vitro. Normann SJ; Cornelius J Cancer Res; 1987 Apr; 47(8):2067-72. PubMed ID: 3828996 [TBL] [Abstract][Full Text] [Related]
5. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy. Vaage J Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431 [TBL] [Abstract][Full Text] [Related]
6. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin. Dubois JB; Serrou B Cancer Res; 1976 May; 36(5):1731-4. PubMed ID: 773530 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment. Alvarez V; Lodillinsky C; Umerez S; Sandes E; Eiján AM Int J Mol Med; 2005 Oct; 16(4):565-71. PubMed ID: 16142388 [TBL] [Abstract][Full Text] [Related]
8. Differences in biological activity among batches of lyophilized tice Bacillus Calmette-Guérin and their association with clinical course in Stage I lung cancer. Bennett JA; Gruft H; McKneally MF; Zelterman D; Crispen RG Cancer Res; 1983 Sep; 43(9):4183-90. PubMed ID: 6347367 [TBL] [Abstract][Full Text] [Related]
9. BCG immunization for the lymphoid leukemia line (LSTRA) in CDF1 mice. Chaparas SD; Chirigos M; Pearson J; Sher N Natl Cancer Inst Monogr; 1973 Dec; 39():87-8. PubMed ID: 4595328 [No Abstract] [Full Text] [Related]
10. Cellular and humoral immunity to leukemia cells in BCG-induced growth control of a murine leukemia. Olsson L; Florentin I; Kiger N; Mathé G J Natl Cancer Inst; 1977 Oct; 59(4):1297-306. PubMed ID: 904001 [TBL] [Abstract][Full Text] [Related]
15. BCG-induced murine effector cells. I. Cytolytic activity in peritoneal exudates: an early response to BCG. Tracey DE; Wolfe SA; Durdik JM; Henney CS J Immunol; 1977 Sep; 119(3):1145-51. PubMed ID: 330748 [No Abstract] [Full Text] [Related]
16. Bacillus Calmette-Guérin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells. Lodillinsky C; Umerez MS; Jasnis MA; Casabé A; Sandes E; Eiján AM Int J Mol Med; 2006 Feb; 17(2):269-73. PubMed ID: 16391825 [TBL] [Abstract][Full Text] [Related]
17. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells. Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767 [TBL] [Abstract][Full Text] [Related]
18. Influence of immunisation with Mycobacterium bovis bacillus Calmette-Guérin on the sensitisation to inhaled allergens after infection with respiratory syncytial virus. Vonberg RP; Mueller M; Emmendoerffer A; Freihorst J Clin Exp Med; 2005 Dec; 5(4):177-83. PubMed ID: 16362797 [TBL] [Abstract][Full Text] [Related]
19. BCG in cancer immunotherapy: experimental and clinical trials of its use in treatment of leukemia minimal and or residual disease. Mathé G; Weiner R; Pouillart P; Schwarzenberg L; Jasmin C; Schneider M; Hayat M; Amiel JL; de Vassal F; Rosenfeld C Natl Cancer Inst Monogr; 1973 Dec; 39():165-75. PubMed ID: 4595314 [No Abstract] [Full Text] [Related]